Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's either a pp or a requiired r/s by a financial institution whom will require DNAP to be worh X dollars, instead of
x cents worth!!!!! The pp is a given for any small penny stock trying to gain market presence and share! Look at
SSPC, they are increasing their shares to prepare for expansion of a legitimate product. Shareholders are the
ultimate concern of public trading companies, at least they should be! Increasing the equity/assets of a company
is a given for officers of a company as well. They want the BIG BUCKS too! Research and revenues do not grow
on trees. Someone has to "cough up the venture cash!" I cannot see where a few more million shares will hurt DNAP!
The end results will more than off set the dilution; one or two solutions and DNAP will be on it's way, imho!!!!
Take care, IVRT
The Bear Market is Over- The Bull is Back!
Corporate performance has been dismal as the economy continues to wrestle with the
current slow down. One wonders why stocks would begin to come back with no sign of an
economic rebound? The answer is simple and can be found by examining events of the
past year.
Understanding The Past To Predict The Future
One year ago the NASDAQ was testing 3000, down from the high of 5200 in March. This
drop correctly reflected the "irrational exuberance" priced into stock values.
The market retested 4200 twice during the summer of 2000 as stocks trended higher.
The nastiest Bear in the history of NASDAQ sunk its teeth into the wallets of investors
from September of 2000 into early April of 2001 leaving many portfolios decimated.
Stocks prices were destroyed in the 4th quarter of last year, but news of layoffs, earnings
disappointments and lack of visibility did not surface until January. Downgrades were
coming in hordes from Wall Street analysts after stocks had already gotten clobbered.
The market knew the business climate was terrible long before investors heard it from
Wall Street and the financial media.
Stocks are now beginning to trend higher in the absence of corporate performance, which
is puzzling to many investors. We are experiencing the inverse of last year's bear. The
market is a forward looking mechanism, and today's prices are moving based on the
market's perception of where companies will be in six months.
Experienced money managers know the aggressive interest rate cuts from the FED will
eventually lead to an upturn in corporate performance. Excess supplies of technology from
the overfunded tech sector are being absorbed, and once we arrive at increasing
demand for decreasing inventory companies will rebound.
The market won't go straight up. There will be some pullbacks and hiccups along the way.
We have arrived at the point where pullbacks will be met with buyers, and you should now
put your sidelined capital to work. Just as analysts were behind the curve in the Bear
Market, they are behind now. Don't wait for them to come out with buy recommendations
after stocks have already appreciated 40%. The BULL is back, and the next economic
expansion could be the most prolific in history.
The OTCjournal.com
New E-Mail from C Hall 5/21/01 (from tin on rb, Thanks tin for the email)
Larry,
I was contacted by Craig Hjalmarson from http://www.greedorfear.com/ to participate in
this interview. The next several months look to be a very exciting time for DNAPrint and I
encourage current and potential investors to attend.
Knobias completed their video tour last week and DNAPrint should be up on their
website after Knobias has had the opportunity to do the necessary editing (probably
about 3 weeks). You can register for their service at http://www.knobias.com/ .
Regards,
Craig Hall
Investor Relations
Stockholder, I think we can expect a discovery to be made public in the near term. TBFC has stipulated more cash will be made available per benchmarks! The retinome project should garner DNAP more cash!!! The public release of this discovery will probably not move DNAP to much, but it should create greater investor awareness of DNAP's potential! IMHO
Have a good day too!
IVRT
Emory University, NuTec Sciences, IBM Develop Genomics-Based System to Individualize Cancer Treatments
http://news.moneycentral.msn.com/ticker/article.asp?Symbol=US:IBM&Feed=BW&Date=20010503&...
Pops, I could not have said it any better, I second your post!!!!!!!
Missed you in the GL chat room yesterday!!!!!
IVRT
Thanks for the invite! My biotech pick is DNAP! Link to DD is http://www.sockthestocks.com/profiles/dnap.htm
I also like generic drug Co. DYGN!!! It could be the next Barr, Geneva or old Rugby!!!! DYGN DD link is http://ragingbull.lycos.com/mboard/boards.cgi?board=DYGN&read=7093
NEOP and MABA are two other biotech Co that I follow!!!
DNAPrint Announces Another Blood Supply Relationship
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cbw%5C2001%5C04%5C12...
Always glad to help my director, pops!!! Hope you are doing well too!
IVRT
jorjenzak, we already knew that some people were "fast acetylators" and others were not! This meant that certain people could metabolize a drug faster than others! Also, the liver helps conjugate certain drugs to make them water soluble. Water solubulizing occurs by two primary paths: glucoronidation or sulfonation! These pathways form water soluble metabolites that can be eliminated by the kidney! The only thing these guys did was to provide a test that helps determine which people metabolize drugs faster than others or conjugate drugs better than other people.
DNAP is going a lot "deeper" than this!!!
IVRT
Any diabetics on the board today? Read this!
Check out CYGN, they have FDA approval on a glucose watch that can check you blood
sugar four times an hour without a needle stick! This will help a lot of diabetics control
their hypo and hyperglycemias!!!
Hear about it here:
http://www.quote.com/quotecom/news/story.asp?symbols=CYGN&story=20822715
FEMS: This looks new, at least for me, I do not see the NIH grant mentioned here as before!!!
DNAPrint Genomics has developed a Front-End Management System (FEMS) software product to
manage the workflow of DNA through automated DNA analysis equipment. FEMS is a software
product developed by DNAPrint programmers to refine and store information about raw sequence
alignments, candidate SNPs and biochemical reagents necessary for conducting polymorphism
discovery experiments (i.e. oligonucleotides). The SNiPdoc system operates FEMS works closely with
the Finch database licensed by the company from Geospiza. The most recent versions of FEMS
include software that is specifically suited for the design of re-sequencing (sequencing the same gene
from multiple donors) experiments starting with raw human genome data files (NCBI Genbank). The
software system defines "important" and "unimportant" regions of a human genome DNA sequence
file, designs primers to flank pertinent regions of the file and formats these primers for easy
ligonucleotide ordering from third party vendors. The software accomplishes in seconds what it
previously took a scientist an hour or more to accomplish during the tedious process of experimental
design.
"SNIPdoc" SNP discovery system
The Company maintains a full, cutting edge high throughput polymorphism screening facilitity and the
SniPdoc system is the discovery search engine for this facility. SniPdoc is a software system that and
aligns raw DNA sequence data from multiple donors, and uses proprietary statistical routines to find
reliable discrepancies between these sequences. The data is formatted and deposited into a relational
database system."
I quit callling Craig back in August of 2000! I see very little to be gained by talking to the PR dude! Emails do not seem to offer much more than affirmation of postive information!!! The general market is down big time and it is tax time again!!!! Traders are moving money out of OTCbb!
I cannot see where one can call the stock a stinker, when DNAP is only seven or eight months old and has not generated significant revenues as to date!!! You are getting impatient!!!! You may feel better by closing out your position in DNAP and waiting for the market to turn around!!!! Of course it is your call DEJ!!!
SNP Applications Seen Saving Healthcare Industry $1 Billion by 2010
http://www.genomeweb.com/
UPDATE 1-Biotechs up on analyst upgrades, bargain hunting
http://www.quote.com/quotecom/news/story.asp?symbols=AMGN&story=20608704
The Genome as Cuisinart
http://www.quote.com/quotecom/news/story.asp?symbols=CRA&story=20519270
DNAPrint Joins Internship Program
http://www.quote.com/quotecom/news/story.asp?symbols=DNAP&story=20504736
It will not be long, before we see some valuable alliances and collaborations come DNAP's way, with the release of the lastest DNAP PR! The small biotech companies that present at these conferences usually have deals within six months after their presentations! Imho, I think it is nearing the time to "buckle up" and enjoy the DNAP ride!!!! DNAP will be turning heads with this latest PR! This PR is "meat on the bone" for BIG PHARMA to "chomp down on!!!!!"
Have you seen this at DNAP web site?
SNIPdoc" SNP discovery system
The Company maintains a full, cutting edge high throughput polymorphism screening facilitity and the SniPdoc system is the discovery search engine for this facility. SniPdoc is a software system that and aligns raw DNA sequence data from multiple donors, and uses proprietary statistical routines to find reliable discrepancies between these sequences. The data is formatted and deposited into a relational database system."
DNAPrint genomics, Inc. Eligible for Quotation on NASDAQ OTC Bulletin Board
http://www.quote.com/quotecom/news/story.asp?symbols=DNAP&story=20114208
Wow, the DNAP soup pot is starting to boil again and it is running over which hypotheical veggies! You name it and we can expect to see it this week or next! Oh, no I think I am hyperventilating or sometime! My nerves are a little dulled by the last few months, but keep up the rumors and I may work myself into a frenzy again. Heck, might even make a bundle of money too, but I will wait and see and will not complain one bit if it happens!!!!
DNAP LONGGGGGGGGGGGGGGGGG here!!!!!!!!! Just waiting for a BIG dose of OTCBB DNAP listing reality to set in!!!!!
3rd institution picks up 25000 shares of DNAP!
COMPTON CAPITAL MANAGEMENT INC /RI
http://www.lionshares.com/secmasdetails.cfm?CUSIP=23324Q103&SEARCH=symbol&sort=net_chg&order=DESC&records=15&FirstRow=1&LastRow=15&SID=DSUD001%203046476467211222000161411%20%20%20%20%2016A13EDA73C5B25A6ACBCB49845D34DDC&PID=
Oh ,yes I think this seconadary financing may be pay back for TBF's loan to DNAP. TBF wants their two million back by doing this private placement! What do you think? Conjecture at this point, however!!!
Ok, we all are adults here and we knew that this was going to happen. You see it in all penny stocks that need to grow. There is the need for cash, the company cannot print money!!! So they look for venture capitalists. This tells me that DNAP does not have a solid cash alliance with anyone at this time, imho. In addition, DNAP has restricted shares that will most likely be put into the market place ahead of the private placement stocks down the road. This will cause a cascade of events that will lead to dilution and the need for a reverse split to satisfy another round of equity financing! At this point DNAP will be on it's way to stardom or we will be waiting the full ten years for a payoff! Either way, if you believe in Dr Tony and his science, there is really no way around this, unless he can get an equity deals through collaborations and alliances as we are all praying will happen, before a r/s happens as required by some financial loan institutions!
Plus, if someone tells you they need money to go 100 times faster, the bottom lines is always the same, they really need money to stay afloat. You burn the candle twice as bright and it will go out twice as fast!
DNAP has their new address on this web page! Check it out!!!
http://www.dnaprint.com./index.cfm?fuseaction=content&id=90
Welcome to the board mbeale, the chat room dried up at 10:30 p.m.! We had 20 posters and it was a lot of fun.
Hello everyone, we had a bunch of posters in the IHUB DNAP chat room tonight, pops counted 20, I believe. We had a good time too! I know that there are some tech problems with the chat room and some folks using AOL. One possible solution is (if you want too) is to use a Netscape or IE browser to enter the chat room. Personally, I am using Netscape 4.76. However, IHUB Matt is working with DD, to correct the AOL issue! please have patience!
IVRT
crthbull, hello I am a new investor in this stock! I manage the DNAP at IHUB! Can you tell me
if the company will get the financing they need this year? Looks like a big project to roll out
20,000 miles of fibre optic lines. Do they have the clout to bring about this type of financing!
They have about 200,000,000 shares(?), but the o/s is not to large! Do you think they will give
stock warrants to venture capitalists as a means of getting the money?
INVT plan looks good on paper!!! TIA
IVRT
Email from Craig Hall regarding listing delay:
IVRT:
We heard back from the NASD yesterday afternoon. They came back with 5 questions. Our lawyers are answering those questions today and we will resubmit tomorrow. It will be approximately 3 weeks before we hear back from the NASD. Again, this is the final step in DNAPrint's quest to be listed on the OTC-BB.
Regards,
Craig Hall
Investor Relations
Biology Lobbying Group Calls for More Genomics Funding
http://www.genomeweb.com/
NEW: Great profile of DNAP at http://www.marketmillionaires.com/
The 8th BioPartnering Europe Conference in London Proves That The Biotechnology Industry Is Definitely on the Up
WEDNESDAY, OCTOBER 18, 2000 12:19:00 PM EST
LONDON, Oct 18, 2000 /PRNewswire via COMTEX/ -- The 8th BioPartnering Europe conference, which took place in London on 16-17 October 2000, attracted a record number of delegates and exhibiting companies this year, with the conference mood reflecting the increasing excitement within the industry.
Monday afternoon saw keynote presentations and a panel session focused on the growth and financing trends within the industry, which concluded that the year 2000 has seen a massive upturn in the sentiment towards the biotech sector. The first quarter of 2000 alone has seen more money raised than in the whole of 1999. So far, $6 billion has been raised this year to finance biotech firms, compared to $0.9 billion in 1999.
Rodney Young, Managing Director and Head of the European Healthcare Investment Banking group at SG Cowan, believes that this has been partly due to the increased demand placed on the industry to deliver on the successful sequencing of the human genome earlier this year, and also due to dotcom companies losing their appeal with investors.
Nick Low****, Managing Director at E.M. Warburg, Pincus & Co. International, supported this notion and added that the industry is "in a much healthier shape" than a year ago.
The Monday morning session involved a panel session where three speakers from biotechnology companies discussed a new paradigm based on the integration of diverse information technology (IT) resources with the life science R&D, and how the resulting increase in information is being managed using databases, processes, systems and desktop applications. The session concluded that the current drug discovery and development processes are driven by new generation high technologies such as bioinformatics, and that older approaches, classically used in front line drug development, are now used as a secondary measure to confirm results predicted using the more modern technologies.
The positive sentiment within the industry has been supported by the positive announcements made during the day by leading biotechnology companies from around the world:
-- `Oxford BioMedica obtains approval for TroVax(TM) to enter trials for
colorectal cancer'
-- `Prolifix appoints clinical advisory board as key cancer compounds
progress towards clinical development'
-- `New NMR-based technology to shorten drug discovery chemistry from
years to weeks'
-- `Neurotech S.A. builds powerful patent portfolio covering cell therapy
and protein delivery'
-- `D-Pharm completes Phase I of its DP-b99 testing'
-- `D-Pharm receives technology patent'
SOURCE BioPartnering Europe Conference
CONTACT: Media, Nikul Odedra, Senior Account Manager,
n.odedra@hccdefacto.com, or Caroline Stupnicka, Account Executive,
c.stupnicka@hccdefacto.com, both of HCC De Facto, +44-20-7496-3300; or
Delegates, Nancy Connelly of Technology Vision Group LLC, 831-464-7100,
neconnelly@techvision.com
http://www2.marketwatch.com/news/article.asp?doctype=2005&value=3354&query=NURO&searchoption=ticker&property=sid&display=NURO&source=&guid={3E33F707-3F94-4130-8DA4-BD565298691B}
... "Once a technology becomes hot in this field, word gets around
quickly, and a lot of deals are made," notes Phillips L. Kuhl, president of CHI. "But
acquiring these technologies is extremely expensive, particularly since you usually
need more than one to really enter the field."...
The article is located at
http://www.genometriconference.com/index2.htm
Click on the TRInews Articles button on right side of page and then select
The Leading Genomic Dealmakers: Strategies and
Technological Platforms
The SNiPdocTM page has changed several times, since October of last year. The main differences now are the inclusion of ORCHID, insertions of "extremely competitive" and "collaborative work." This particular page has never appeared timid, but now there is a sense of accomplishment and the need for people to know that DNAP and Orchid have something worth using!!! It may be me, but I see "BIG" DNAP revenues, whenever I read this page (IMHO):
http://www.dnaprint.com./index.cfm?fuseaction=content&id=15
DNAPrint is currently one of a select group of companies with a license to use Orchid genotyping technology on a contract fee-for-service basis. Our rates per genotype are extremely competitive. For contract fee-for-service, or other collaborative work with DNAPrint genomics, please contact Dr. Tony Frudakis at 941-351-4543 or dnaprint@gte.net.
FYI : Email from Craig regarding PENSAT IPO and some of TBFC's restricted stock positions!
IVRT,
These are all companies that Tampa Bay Financial Funded and took public. We do not own these companies, but we hold a restricted stock position in all of them. I am currently working with DNAPrint Genomics and will be involved in the Pensat IPO (coming February 1st). We will have the Pensat investor information available the week of the 29th and I will send you out the info at that time. For now, you can go to the Pensat website at www.pensat.com.
Here are the investor relations people for our other companies:
(1) Heroes, Inc (HERS)
Christopher Baker 404-915-5485
(2) American Communicatons (ACEN)
Steve Wagoner 941-923-1949 swagoner@tbfcorp.net
(3) GRG Inc (GRGI)
Scotty Miller 727-550-2442
(4) Pensat (symbol to be announced February 1st)
Craig Hall 941-341-0136 chall@tbfcorp.net
Regards,
Craig Hall
----- Original Message -----
From: CMAACCESS
To: Richard Craig Hall
Sent: Wednesday, January 17, 2001 10:36 PM
Subject: Info
Craig, can you give me any information on ACEN, GRGI and PENSAT? Are all of these companies owned by TBFC? I am thinking of investing in ACEN and PENSAT! Are there mergers on the wire that you can tell me about? I am interested in investing in TBFC companies, but I need more info. May be you can send me investor packets on them, including PNAC. Can you tell me what type of spin-off is planned for ACEN? Will it be PENSAT? I am not too familiar with these companies. TIA
Here is my address again, Craig!
IVRT
Anyone heard about Stocktribe's DNAP visit?eom
Q&A: New Orchid Life Sciences Head Discusses SNP Strategy
Written By: Marian Moser Jones
NEW YORK, Jan 19 - Ten days ago, Jack Ball, Amersham Pharmacia Biotech's North America president, left his job to take charge of Orchid Biosciences’ life sciences division. GenomeWeb spoke to Ball, 53, Friday about his decision to lead the division as well as Orchid’s position in the competitive SNP analysis market.
GW : In your new position as life sciences senior vice president what will you be doing?
Ball: This position was created so Dale [Pfost, Orchid’s CEO] could spend more time on M&A activities instead of running the day-to-day business in the life sciences division. There are three business units. One is GeneScreens, which is involved in paternity and forensic testing. The second is the pharmaceutical value creation division, which is creating pharmaceutical value out of SNPs. [Then] Orchid’s life sciences group markets products and services for genotypic analysis.
GW: AP Biotech is a well established company. Why did you leave AP Biotech for a company like Orchid, which is smaller and less mature?
Ball: It’s more fun here. It’s more fun to build something than it is to run a large established business. [When change is needed] We can turn on a dime. [AP Biotech] is a behemoth. I guarantee it [would] take AP Biotech three years to [change direction].
GW: The SNP analysis market is getting pretty competitive right now, with Sequenom’s MassArray, AP Biotech introducing the Sniper, Qiagen and other companies doing SNP analysis. What does Orchid offer in particular to this intensely competitive market?
Ball: The most exciting thing Orchid offers is the intellectual property of primary extension. We have signed deals with AP Biotech, ABI, [and] NEN Perkin Elmer to use primer extension as the key technology on their existing sequencing platforms. We really own the space from an IP perspective. There are other companies with other instruments that come in with genome-wide scanning. But as the market develops, where you are looking at individuals as opposed to population density, primer extension will be the primary technology.
GW: What is primer extension and how does it work?
Ball: We designed a primer that abuts the SNP location. We then use a DNA polymerase to add the next base in the sequence. We then have a reporter molecule on that base that tells us which base has been added, and that defines the SNP.
GW: What about Sequenom? Sequenom is chomping on your heels in doing deals on their Massarray systems.
Ball: At the state of the market right now, Sequenom is probably our biggest competitor. Sequenom will help the market find the frequency and the interesting SNPs out there. Once that’s done, that’s when we really start to make the money. Because that’s when we start to get utility out of individual SNPs. That’s when people are going to be paying to do SNP analysis on large numbers of people.
I think we will begin to dominate the space as we begin looking at individual SNP panels or groups of individuals beginning to define subsets of populations, adverse drug reactions, propensities for certain medical conditions. We also believe our platform is more expandable than theirs into the million SNPs range. They are going to be limited when it comes to more directed studies, where you are looking at a large number of individuals for particular SNPs. Say you want to go look in at a particular SNP in a million individuals. They are going to have a great deal of difficulty scaling to that sort of project.
GW: Do you see Orchid branching out of SNP analysis into wider life sciences applications?
Ball: Anything is possible. But I would prefer not to comment on this.
GW: What is your vision for Orchid’s life sciences operations?
Ball: My vision is to build a diverse group of platforms that will serve the wide needs of the market. There are going to be some people that want to do a few SNPs on a lot of people, and some people that want to do a few SNPs on a few people, and a few [groups] are going to do a lot of SNPs on a lot of people.
Right now there is one primary platform, the 25k, which has a capacity of 25,000 genotypes per day. The next platform, the 5K, will be on a lower scale, then another platform will be the 1K, which will do 1000 genotypes per day. Also, we’re developing SNPcode, an assay using primer extension that runs off of an instrument base of Affymetrix machines using the affymetrix chips. Last week we announced a collaboration with Exelixis on SNPcode.
GW: What is Orchid’s greatest weakness in the current market?
Ball: Our greatest weakness is the speed with which we are growing and our ability to attract talent. We are trying to get talented people into the Princeton area. And even with the general slowdown seen across the US, the New York-New Jersey area still has the tightest job market anyplace in the United States.
GW: How do you see the SNP analysis market growing in the next five years?
Ball: It’s difficult to say. There will be a lot of people doing a lot of SNP scoring over the next five years. The big question we all have is ‘will there be utility in the SNPs that are found?’ That’s a crystal ball question. I believe it because I believe that’s the basis of genetic diversity, but I can’t tell you that that’s the case.
DNAP has been in the forty cent(s)/share range before! It was on August 31st! September too,
made July and early August DNAP shareholders money!
If DNAP mailed the two answers on 01/05/01, and there are no follow-up questions from the NASD, DNAP could be listed this week or next Monday! According to Gladreaper's post, the NASD has a 7 to 10 day turnaround! IMHO, the listing window for DNAP is possibly, within the next seven days! After six months of waiting, I am getting Excited about the listing!!!
Of course this only my opinion (not fact), and this is not a recommendation to buy or sell!!!